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Introduction {#emmm201809408-sec-0001}
============

Osteosarcoma (OS) is the most common primary tumor of the bone originating from transformed mesenchymal cells (Mirabello *et al*, [2009](#emmm201809408-bib-0028){ref-type="ref"}). It predominantly occurs in young adults with about 400 new cases diagnosed in the United States each year (Ottaviani & Jaffe, [2009](#emmm201809408-bib-0034){ref-type="ref"}). Due to the lack of major therapeutic progress, the 5‐year survival of OS patients did not significantly improve since the 1980s, thus raising the need for novel treatment strategies (Ando *et al*, [2013](#emmm201809408-bib-0001){ref-type="ref"}).

To design better therapeutic options for OS patients, it is essential to understand the molecular pathogenesis of the disease. Mutations of the tumor suppressor genes p53 and Rb are major known events inducing osteosarcomagenesis (Marina *et al*, [2004](#emmm201809408-bib-0025){ref-type="ref"}). Moreover, overexpression of proto‐oncogenes like c‐Myc or c‐Fos was reported to play an essential role during bone tumor formation (Wu *et al*, [1990](#emmm201809408-bib-0054){ref-type="ref"}; Gamberi *et al*, [1998](#emmm201809408-bib-0008){ref-type="ref"}). Transgenic mice expressing *c‐fos* under the control of the ubiquitously expressed *H2kb* promoter (H2‐*c‐fos*LTR) develop bone tumors with 100% penetrance (Ruther *et al*, [1989](#emmm201809408-bib-0040){ref-type="ref"}; Grigoriadis *et al*, [1993](#emmm201809408-bib-0009){ref-type="ref"}). Previous studies reported that OS formation in these mice depends on the expression of endogenous *c‐fos* and on the activation and stabilization of c‐Fos protein via the MAPK‐regulated S6 kinase RSK2 (Wang *et al*, [1995](#emmm201809408-bib-0048){ref-type="ref"}; David *et al*, [2005](#emmm201809408-bib-0006){ref-type="ref"}).

Epidermal growth factor receptor (EGFR) expression occurs in 55--81% of all OS cases; however, its clinical relevance in OS development is still controversial (Oda *et al*, [1995](#emmm201809408-bib-0033){ref-type="ref"}; Wen *et al*, [2007](#emmm201809408-bib-0052){ref-type="ref"}; Do *et al*, [2009](#emmm201809408-bib-0007){ref-type="ref"}; Wang *et al*, [2018](#emmm201809408-bib-0051){ref-type="ref"}). EGFR can control c‐Fos via the MAPK pathway, and changes in *c‐fos* expression after anti‐EGFR treatment in cell lines have been suggested to predict therapy success (Jimeno *et al*, [2006](#emmm201809408-bib-0015){ref-type="ref"}; Murphy & Blenis, [2006](#emmm201809408-bib-0030){ref-type="ref"}). Interestingly, EGFR significantly correlates with ERK activation in human OSs (Do *et al*, [2009](#emmm201809408-bib-0007){ref-type="ref"}). Moreover, we recently showed that EGFR is essential in osteoblasts for bone development via ERK‐dependent regulation of IGF‐1/mTOR signaling (Linder *et al*, [2018](#emmm201809408-bib-0022){ref-type="ref"}). Because of the relatively low incidence rate of OS, clinical trials with inhibitors or antibodies against EGFR could not establish a clear therapeutic benefit in bone tumor formation, due to low statistical power (for review, see Wang *et al*, [2014](#emmm201809408-bib-0049){ref-type="ref"}). Preclinical studies with EGFR inhibitors, which were mainly performed *in vitro* using human OS cell lines or immunodeficient xenograft models, have reported contradictory results (Messerschmitt *et al*, [2008](#emmm201809408-bib-0027){ref-type="ref"}; Lee *et al*, [2012](#emmm201809408-bib-0021){ref-type="ref"}; Sevelda *et al*, [2015](#emmm201809408-bib-0041){ref-type="ref"}; Gvozdenovic *et al*, [2017](#emmm201809408-bib-0012){ref-type="ref"}).

In the present study, we aimed to understand the role of EGFR during OS development using the autochthonous H2*‐c‐fos*LTR mouse model and human OS tumor biopsies. Since EGFR can activate S6 and RSK2, we hypothesized that EGFR might act as the upstream receptor inducing OS formation in H2*‐c‐fos*LTR mice. We found that EGFR signaling is essential in osteoblasts for bone tumor formation and progression. We also identified EGFR as the upstream receptor regulating endogenous *c‐fos* expression and stabilizing and activating c‐Fos protein via MAPK/CREB signaling. In addition, we show that EGFR and c‐Fos co‐expression inversely correlate with OS patient survival. These findings provide strong evidence that EGFR and c‐Fos expression levels could be used as powerful clinical biomarkers to identify OS patients likely to benefit from anti‐EGFR therapy.

Results {#emmm201809408-sec-0002}
=======

EGFR is essential for c‐Fos‐dependent OS formation {#emmm201809408-sec-0003}
--------------------------------------------------

In order to investigate the role of EGFR signaling in OS development, we first analyzed *Egfr* and *c‐fos* mRNA expression in normal bones from wild‐type (wt) and H2*‐c‐fos*LTR mice, as well as in OSs from H2*‐c‐fos*LTR mice. Both *Egfr* and *c‐fos* levels were significantly elevated in OSs, whereas no genotype depending differences were observed in normal bones (Fig [EV1](#emmm201809408-fig-0001ev){ref-type="fig"}A and B). To assess whether EGFR signaling is required for c‐Fos‐dependent bone tumors, we genetically attenuated EGFR signaling by breeding H2*‐c‐fos*LTR mice to mice carrying the hypomorphic *Egfr waved‐2* allele (*Egfr* ^wa2/wa2^), leading to reduced EGFR activation (Luetteke *et al*, [1994](#emmm201809408-bib-0024){ref-type="ref"}). H2*‐c‐fos*LTR/*Egfr* ^wa2/wa2^ mice developed significantly less and smaller bone tumors, indicating that EGFR is essential for bone tumor initiation (Fig [1](#emmm201809408-fig-0001){ref-type="fig"}A--C). Furthermore, serum levels of alkaline phosphatase (ALP), a clinically used indirect OS biomarker (Ren *et al*, [2015a](#emmm201809408-bib-0037){ref-type="ref"}), were also significantly reduced in H2*‐c‐fos*LTR/*Egfr* ^wa2/wa2^ mice (Fig [1](#emmm201809408-fig-0001){ref-type="fig"}D). To investigate whether pharmacological EGFR inhibition would also show therapeutic benefits, we treated 2‐month‐old H2‐*c‐fos*LTR/*Egfr* ^wt^ mice with visible OS, over a period of 5 months with erlotinib (Fig [EV1](#emmm201809408-fig-0001ev){ref-type="fig"}C). Inhibition of EGFR phosphorylation by erlotinib (Fig [EV1](#emmm201809408-fig-0001ev){ref-type="fig"}D) induced tumor stasis indicated by significantly reduced tumor number, tumor size, and ALP serum levels, when compared to vehicle‐treated controls (Fig [1](#emmm201809408-fig-0001){ref-type="fig"}E--H). mRNA expression analysis of OS from H2‐*c‐fos*LTR mice and from human OS from a publicly available dataset \[E‐GEOD‐39058 (Kelly *et al*, [2013](#emmm201809408-bib-0017){ref-type="ref"})\] revealed that EGFR might get activated by an autocrine loop as EGFR ligands were expressed both in mouse and human OS with *Hb‐EGF* being the highest (Fig [EV1](#emmm201809408-fig-0001ev){ref-type="fig"}E and F). In line, OSs from H2*‐c‐fos*LTR mice showed significantly elevated expression of *Hb‐EGF* and *TGFa* as compared to normal bones (Fig [EV1](#emmm201809408-fig-0001ev){ref-type="fig"}G and H).

![H2‐*c‐fos* LTR mice show elevated mRNA expression of *Egfr* and *c‐fos* and upregulation of the EGFR ligands *Hb‐EGF* and *TGFa*\
A*Egfr* mRNA expression in normal wildtype (wt) bones and in normal bones or OSs of H2‐*c‐fos* LTR mice (*n *=* *4).B*c‐fos* mRNA expression in normal wt bones and in normal bones or OSs of H2‐*c‐fos* LTR mice (*n *=* *4).CErlotinib treatment scheme: 2‐month‐old H2‐*c‐fos* LTR/Egfr^wt^ mice were treated with vehicle or erlotinib (25 mg/kg, 5x/week for 3 x 4 weeks with 2 x 4 week non‐treatment interval in‐between). X‐ray analysis and blood sampling for tumor number/size quantification and serum ALP measurement were performed once a month.DpEGFR IHC analysis of OSs from 7‐month‐old H2‐*c‐fos* LTR/Egfr^wt^ mice after vehicle or erlotinib treatment. Scale bars: 500 μm (lower magnification), 100 μm (higher magnification).EEGFR ligand mRNA expression in OS from H2‐*c‐fos* LTR mice (*n *=* *4), normalized to *Egf*.FEGFR ligand mRNA expression in human OS (*n *=* *42, data analyzed from publicly available dataset E‐GEOD‐39058).G*Hb‐EGF* mRNA expression in normal wildtype (wt) bones and in normal bones or OSs of H2‐*c‐fos* LTR mice (*n *=* *4).H*TGFa* mRNA expression in normal wildtype (wt) bones and in normal bones or OSs of H2‐*c‐fos* LTR mice (*n *=* *4).Data information: Data are shown as mean ± SEM. *P*‐values were calculated by one‐way ANOVA followed by Bonferroni multiple comparison test.](EMMM-10-e9408-g003){#emmm201809408-fig-0001ev}

![EGFR signaling is essential for c‐Fos‐dependent bone tumor formation\
AX‐ray analysis of 6‐month‐old H2*‐c‐fos*LTR/Egfr^wa/+^ and H2*‐c‐fos*LTR/Egfr^wa/wa^ littermates. Scale bars: 1 cm.BBone tumor number per mouse at 5--6 months of age (*n* = 23 wa/+, 15 wa/wa).CQuantification of tumor size in tibiae at 5--6 months of age (*n* = 23 wa/+, 15 wa/wa).DAlkaline phosphatase (ALP) levels in the serum at endpoint (age = 5--6 months; *n* = 16 wa/+, 11 wa/wa).EX‐ray analysis before (age = 2 months) and after (age = 7 months) vehicle or erlotinib treatment. Scale bars: 1 cm.FQuantification of tumor number during treatment (*n* = 6 vehicle, 5 erlotinib).GTumor size during treatment (*n* = 6 vehicle, 5 erlotinib).HAnalysis of serum ALP levels during treatment (*n* = 5).IPET summation images (0--90 min) in horizontal (upper panel) and coronal view (lower panel) depicting \[^11^C\]erlotinib distribution in one H2‐*c‐fos*LTR/*Egfr* ^wt^ mouse (M125). Anatomical structures are labeled with arrows (T, tumor; L, liver; H, heart; B, brain). Scale bars: 1 cm.JConcentration--time curves of \[^11^C\]erlotinib in bone tumors in right scapula of three H2‐*c‐fos*LTR/*Egfr* ^wt^ mice measured with PET. Broken line indicates threshold for *in vitro* effect of erlotinib (1 μM).Data information: Data are shown as mean ± SEM. *P*‐values were calculated by unpaired, two‐tailed *t*‐test (B--D) or by two‐way ANOVA followed by Bonferroni multiple comparison test (F--H).](EMMM-10-e9408-g002){#emmm201809408-fig-0001}

To investigate whether erlotinib showed effective penetration into OSs, 6‐month‐old H2‐*c‐fos*LTR/*Egfr* ^wt^ mice with OS, as confirmed with Na\[^18^F\]F PET imaging, underwent PET scans after i.v. injection of \[^11^C\]erlotinib at a dose of 2 mg/kg, which corresponds to a human therapeutic dose. Previous results indicated negligible metabolism of \[^11^C\]erlotinib in mice over the duration of a PET scan, so that radioactivity signal in OSs of H2‐*c‐fos*LTR/*Egfr* ^wt^ mice can be expected to be only composed of unmetabolized \[^11^C\]erlotinib, thereby allowing for quantification of erlotinib concentrations in tumor tissue (Traxl *et al*, [2015](#emmm201809408-bib-0044){ref-type="ref"}). PET images revealed that erlotinib penetrated into OSs, while it was excluded from the brain as a pharmacological sanctuary site due to efflux transport at the blood--brain barrier (Fig [1](#emmm201809408-fig-0001){ref-type="fig"}I). Maximum erlotinib concentrations in OSs of individual animals ranged from 3.9 to 10.2 μM, which is in a similar range as peak plasma concentrations of erlotinib achieved in cancer patients after oral dosing (Fig [1](#emmm201809408-fig-0001){ref-type="fig"}J; Katsuya *et al*, [2015](#emmm201809408-bib-0016){ref-type="ref"}).

EGFR in osteoblasts promotes OS formation in H2‐*c‐fos*LTR mice {#emmm201809408-sec-0004}
---------------------------------------------------------------

Next, we analyzed the cell type in which EGFR is required to induce OS formation, as we and others have recently shown that EGFR expression in myeloid cells is essential for the development of hepatocellular and colorectal cancer (Lanaya *et al*, [2014](#emmm201809408-bib-0020){ref-type="ref"}; Hardbower *et al*, [2017](#emmm201809408-bib-0013){ref-type="ref"}; Srivatsa *et al*, [2017](#emmm201809408-bib-0043){ref-type="ref"}). We employed the myeloid‐specific *LysM‐Cre* line and the osteoblast‐specific *Runx2‐Cre* line to conditionally delete EGFR in myeloid cells or osteoblasts of H2‐*c‐fos*LTR mice, respectively. EGFR deletion in myeloid cells did not affect OS development in terms of differences in tumor number, burden or serum ALP levels, suggesting that EGFR expression in myeloid cells, which include bone‐resorbing osteoclasts, is dispensable during c‐Fos‐induced OS formation ([Appendix Fig S1A--C](#emmm201809408-sup-0001){ref-type="supplementary-material"}).

In contrast, deletion of EGFR in the osteoblastic lineage (*Egfr* ^ΔOb^) led to significantly reduced tumor number, size, and lower serum ALP levels, demonstrating that EGFR expression in osteoblasts is essential for OS formation (Fig [2](#emmm201809408-fig-0002){ref-type="fig"}A--D). Imaging by μPET/CT with the PET tracer Na\[^18^F\]F, which is both oncotropic and osteotropic, provides a functional readout on osteoblastic cell activity and tumor burden (Broadhead *et al*, [2015](#emmm201809408-bib-0004){ref-type="ref"}; Rohren *et al*, [2015](#emmm201809408-bib-0039){ref-type="ref"}). This analysis revealed that H2‐*c‐fos*LTR/*Egfr* ^ΔOb^ mice showed significantly reduced standardized uptake values (SUV) of Na\[^18^F\]F in pelvic OSs at 4 and 7 months of age (Fig [2](#emmm201809408-fig-0002){ref-type="fig"}E and F) emphasizing the requirement for EGFR in osteoblasts for OS development.

![Osteoblast‐specific EGFR deletion reduces c‐Fos‐driven OS formation\
AX‐ray analysis of 7‐month‐old H2*‐c‐fos*LTR/Egfr^wt^ and H2*‐c‐fos*LTR/Egfr^ΔOb^ littermates. Scale bars: 1 cm.BBone tumor number per mouse at 6--7 months of age (*n* = 22 wt, 11 ΔOb).CQuantification of tumor size in tibiae (*n* = 22 wt, 11 ΔOb).DALP levels in the serum at 7‐month endpoint (*n* = 17 wt, 8 ΔOb).EμPET/CT analysis of 7‐month‐old H2*‐c‐fos*LTR/Egfr^wt^ and H2*‐c‐fos*LTR/Egfr^ΔOb^ littermates.FStandardized uptake values (SUV) of the μPET tracer Na\[^18^F\]F in the pelvic OS of 4‐ and 7‐month‐old H2*‐c‐fos*LTR/Egfr^wt^ and H2*‐c‐fos*LTR/Egfr^ΔOb^ mice. *n* = 6 wt, 4 ΔOb for 4‐month time‐point, *n* = 6 wt, 3 ΔOb for 7‐month time‐point.Data information: Data are shown as mean ± SEM. *P*‐values were calculated by unpaired, two‐tailed *t*‐test.](EMMM-10-e9408-g004){#emmm201809408-fig-0002}

EGFR deletion in osteoblasts decreases proliferation and survival with reduced pRSK2/pCREB/c‐Fos activation {#emmm201809408-sec-0005}
-----------------------------------------------------------------------------------------------------------

As *Egfr* deletion in the osteoblastic lineage affects normal bone development (Linder *et al*, [2018](#emmm201809408-bib-0022){ref-type="ref"}), we next investigated whether EGFR deletion also induces histomorphological changes in c‐Fos‐dependent OS. Bone volume analysis confirmed that osteoblast‐specific deletion of EGFR does not affect the mineralization capacity of OSs (Fig [EV2](#emmm201809408-fig-0002ev){ref-type="fig"}A). Tartrate‐resistant acid phosphatase (TRAP) staining further revealed that EGFR is dispensable for osteoclastogenesis in H2*‐c‐fos*LTR‐derived bone tumors (Fig [EV2](#emmm201809408-fig-0002ev){ref-type="fig"}B). Moreover, expression levels of osteoblast‐specific differentiation markers were not significantly changed in H2‐*c‐fos*LTR/*Egfr* ^ΔOb^ tumors, indicating that EGFR expression from osteoblastic cells does not affect osteoblast cellularity or differentiation in OSs (Fig [EV2](#emmm201809408-fig-0002ev){ref-type="fig"}C and D).

![EGFR deletion does not affect OS morphohistology but leads to reduced proliferation and RSK2‐dependent phosphorylation of c‐Fos at Ser362\
AH&E staining of H2*‐c‐fos*LTR/Egfr^wt^ and H2*‐c‐fos*LTR/Egfr^ΔOb^ bone tumors and quantification of bone volume to total volume (BV/TV) in OS. *n* = 6, scale bars: 100 μm.BTRAP staining and quantification. *n* = 5 wt, 4 ΔOb, scale bars: 100 μm.COsteocalcin IHC staining and mRNA analysis of bone tumors of H2*‐c‐fos*LTR/Egfr^wt^ and H2*‐c‐fos*LTR/Egfr^ΔOb^ mice (*n* = 10). Scale bars: 100 μm.DmRNA expression analysis of whole OS RNA isolated from 6‐month‐old H2*‐c‐fos*LTR/Egfr^wt^ and H2*‐c‐fos*LTR/Egfr^ΔOb^ mice (*n* = 10).ECyclin D1 Western blot analysis of whole OS protein lysates.FWestern blot analysis of whole OS protein lysates isolated from 6‐ to 7‐month‐old H2*‐c‐fos*LTR/Egfr^wt^ and H2*‐c‐fos*LTR/Egfr^ΔOb^ mice.Gp‐c‐Fos (Ser362) IHC staining and quantification shown as % positive cells in OS from H2*‐c‐fos*LTR/Egfr^wt^ and H2*‐c‐fos*LTR/Egfr^ΔOb^ mice. *n* = 6, scale bars: 100 μm.Data information: Data are shown as mean ± SEM. *P*‐values were calculated by unpaired, two‐tailed *t*‐test.Source data are available online for this figure.](EMMM-10-e9408-g005){#emmm201809408-fig-0002ev}

We next assessed the molecular mechanisms by which osteoblast‐specific EGFR deletion impairs OS development. In line with results from the μPET/CT analysis (Fig [2](#emmm201809408-fig-0002){ref-type="fig"}E and F), H2‐*c‐fos*LTR/*Egfr* ^ΔOb^‐derived OSs exhibit significantly reduced proliferation and survival compared to H2‐*c‐fos*LTR/*Egfr* ^wt^ mice, as shown by decreased PCNA and elevated cleaved caspase‐3 IHC staining (Fig [3](#emmm201809408-fig-0003){ref-type="fig"}A). In line, OSs from H2‐*c‐fos*LTR/*Egfr* ^ΔOb^ mice also displayed decreased expression of cyclin D1 mRNA (Fig [3](#emmm201809408-fig-0003){ref-type="fig"}B) and protein (Fig [EV2](#emmm201809408-fig-0002ev){ref-type="fig"}E). Interestingly, OSs from H2‐*c‐fos*LTR/*Egfr* ^ΔOb^ mice had significantly reduced mRNA expression levels of *c‐fos,* while transgenic *c‐fos* (*c‐fos* ^*tg*^) was unaffected indicating that EGFR controls endogenous *c‐fos* expression (Fig [3](#emmm201809408-fig-0003){ref-type="fig"}B). Osteoblast‐specific EGFR deletion also led to reduced pRSK2, decreased pCREB and less c‐Fos‐positive cells in OS, as shown by IHC (Fig [3](#emmm201809408-fig-0003){ref-type="fig"}C) and Western blot analysis of bone tumors from 6‐ to 7‐month‐old mice (Fig [EV2](#emmm201809408-fig-0002ev){ref-type="fig"}F). Moreover, EGFR deletion also significantly reduced RSK2‐mediated phosphorylation of c‐Fos at Ser362 (Fig [EV2](#emmm201809408-fig-0002ev){ref-type="fig"}G). These data indicate that EGFR signaling in osteoblasts is not only essential for proliferation and survival, but also controls endogenous *c‐fos* expression and pRSK2/pCREB/c‐Fos protein stabilization in c‐Fos‐dependent OSs.

![EGFR is essential for proliferation, survival and c‐Fos protein and mRNA expression via RSK2/CREB phosphorylation\
APCNA and cleaved caspase‐3 IHC staining and quantification shown as % positive cells (for PCNA) and as positive cells per mm^2^ (for cleaved caspase‐3) in OS from H2*‐c‐fos*LTR/Egfr^wt^ (*n* = 6) and H2*‐c‐fos*LTR/Egfr^ΔOb^ (*n* = 5) mice. Scale bars: 100 μm.B*Egfr*,*Ccnd1*,*c‐fos* and *transgenic c‐fos* (*c‐fos* ^*tg*^ *)* mRNA expression levels in tumors of H2*‐c‐fos*LTR/Egfr^wt^ and H2*‐c‐fos*LTR/Egfr^ΔOb^ mice normalized to *Tbp*. *n* = 17 wt, 14 ΔOb (*Egfr, Ccnd1*), *n* = 16 wt, 13 ΔOb (*c‐fos*), *n* = 16 wt, 14 ΔOb (*c‐fos* ^*tg*^).CIHC staining and quantification showing pRSK2‐ (*n* = 4), pCREB‐ (*n* = 7 wt, 6 ΔOb), and c‐Fos (*n* = 5)‐positive cells (%) in OS from H2*‐c‐fos*LTR/Egfr^wt^ and H2*‐c‐fos*LTR/Egfr^ΔOb^ littermates. Scale bars: 100 μm.Data information: Data are shown as mean ± SEM. *P*‐values were calculated by unpaired, two‐tailed *t*‐test.](EMMM-10-e9408-g006){#emmm201809408-fig-0003}

EGFR activates pCREB/c‐Fos via MAPK {#emmm201809408-sec-0006}
-----------------------------------

To further demonstrate the cell‐autonomous requirement for EGFR/pRSK2/pCREB/c‐Fos activation in osteoblasts, we next analyzed OS cells isolated from H2‐*c‐fos*LTR/*Egfr* ^ΔOb^ and H2‐*c‐fos*LTR/*Egfr* ^wt^ mice. In line with our *in vivo* findings, we detected strongly reduced protein levels of pCREB and c‐Fos in H2‐*c‐fos*LTR/*Egfr* ^ΔOb^ OS cells (Fig [4](#emmm201809408-fig-0004){ref-type="fig"}A) and significantly reduced expression of *c‐fos* mRNA, while levels of the transgenic *c‐fos* (*c‐fos* ^*tg*^) in OS cells lacking EGFR were comparable to *Egfr* ^wt^ OS cells (Fig [4](#emmm201809408-fig-0004){ref-type="fig"}B). H2‐*c‐fos*LTR/*Egfr* ^ΔOb^ OS cells also showed significantly increased apoptosis and reduced proliferation as evidenced by elevated levels of cleaved caspase‐3 and cleaved PARP (Fig [EV3](#emmm201809408-fig-0003ev){ref-type="fig"}A) and reduced Ki‐67‐positive cells (Fig [EV3](#emmm201809408-fig-0003ev){ref-type="fig"}B) when compared to H2‐*c‐fos*LTR/*Egfr* ^wt^ OS cells.

![EGFR controls c‐Fos via MAPK‐dependent CREB activation in primary OS cells\
AWestern blot analysis of primary OS cells isolated from H2*‐c‐fos*LTR/Egfr^wt^ and H2*‐c‐fos*LTR/Egfr^ΔOb^ mice.B*c‐fos* and *transgenic c‐fos* (*c fos* ^*tg*^) mRNA expression levels in primary H2‐*c‐fos*LTR OS cells after 4× *in vitro* passages, cultured under standard conditions (*n* = 3 independent cell lines).CWestern blot analysis of H2*‐c‐fos*LTR/Egfr^wt^ OS cells treated for 24 h with erlotinib.D*c‐fos* and *c‐fos* ^*tg*^ mRNA expression levels in H2*‐c‐fos*LTR/Egfr^wt^ OS cells treated for 24 h with erlotinib (10 μM) or DMSO as control (*n* = 4 independent cell lines).E, FWestern blot analysis of starved H2*‐c‐fos*LTR/Egfr^wt^ OS cells, pre‐treated with DMSO (1:1,000), afatinib (5 μM), GSK2233470 (10 μM), rapamycin (10 nM), or U0126 (10 μM) for 30 min and stimulated with EGF (50 ng/ml) as indicated.GWestern blot analysis of primary OS cells isolated from a *p53* ^f/f^ *Rb1* ^f/f^ *Osx*‐Cre mouse after 24‐h erlotinib treatment.Hc‐fos mRNA expression levels in *p53* ^f/f^ *Rb1* ^f/f^ *Osx*‐Cre OS cells treated for 24 h with erlotinib (10 μM; *n* = 3).IWestern blot analysis of starved *p53* ^f/f^ *Rb1* ^f/f^ *Osx*‐Cre OS cells, pre‐treated with DMSO (1:1,000) or afatinib (5 μM) for 30 min and stimulated with EGF (50 ng/ml) as indicated.Data information: Data are shown as mean ± SEM. *P*‐values were calculated by unpaired, two‐tailed *t*‐test.Source data are available online for this figure.](EMMM-10-e9408-g008){#emmm201809408-fig-0004}

![EGFR is essential for proliferation and survival of *c‐fos* transgenic OS cells\
AWestern blot analysis of H2*‐c‐fos*LTR/Egfr^wt^ and H2*‐c‐fos*LTR/Egfr^ΔOb^ OS cells starved for indicated time‐points.BQuantification of Ki‐67‐positive primary H2*‐c‐fos*LTR/Egfr^wt^ and H2*‐c‐fos*LTR/Egfr^ΔOb^ OS cells (*n* = 3).CWestern blot analysis of H2*‐c‐fos*LTR/Egfr^wt^ OS cells treated for 24 h with erlotinib as indicated.DQuantification of Ki‐67‐positive H2*‐c‐fos*LTR/Egfr^wt^ OS cells after 24‐h treatment with erlotinib (10 μM; *n* = 3).Data information: Data are shown as mean ± SEM. *P*‐values were calculated by unpaired, two‐tailed *t*‐test.Source data are available online for this figure.](EMMM-10-e9408-g007){#emmm201809408-fig-0003ev}

Moreover, EGFR inhibition with erlotinib resulted in a dose‐dependent downregulation of pRSK2/pCREB/c‐Fos in H2‐*c‐fos*LTR/*Egfr* ^wt^ OS cells (Fig [4](#emmm201809408-fig-0004){ref-type="fig"}C) leading to reduced proliferation as shown by reduced cyclin D1 protein levels (Fig [EV3](#emmm201809408-fig-0003ev){ref-type="fig"}C) and less Ki‐67‐positive cells (Fig [EV3](#emmm201809408-fig-0003ev){ref-type="fig"}D). Erlotinib treatment also led to significantly reduced *c‐fos* mRNA expression without affecting transgenic *c‐fos* mRNA levels, further demonstrating that EGFR signaling specifically promotes transcription of endogenous *c‐fos* (Fig [4](#emmm201809408-fig-0004){ref-type="fig"}D).

We next dissected the molecular signaling pathway downstream of EGFR responsible for activation of pCREB and c‐Fos. Because RSK2 activation depends on ERK1/2 and PI3K‐dependent PDK‐1 signaling (Anjum & Blenis, [2008](#emmm201809408-bib-0002){ref-type="ref"}), serum‐starved H2*‐c‐fos*LTR/*Egfr* ^wt^ OS cells were pre‐treated with inhibitors against EGFR (afatinib), PDK1 (GSK2334470), mTOR (rapamycin), or ERK1/2 (U0126) and afterwards stimulated with EGF (50 ng/ml) for 0, 5, or 30 min (Fig [4](#emmm201809408-fig-0004){ref-type="fig"}E and F). As expected, EGF strongly induced RSK2/CREB phosphorylation after 5 min followed by elevated c‐Fos protein levels after 30 min of stimulation (Fig [4](#emmm201809408-fig-0004){ref-type="fig"}E). Comparable expression patterns were also detected in cells pre‐treated with a PDK‐1 or mTOR inhibitor, suggesting that the PI3K pathway is dispensable for pCREB/c‐Fos activation (Fig [4](#emmm201809408-fig-0004){ref-type="fig"}E). Importantly, when ERK1/2 was blocked, upregulation of the two target proteins was not detected (Fig [4](#emmm201809408-fig-0004){ref-type="fig"}E), indicating that EGF‐induced activation of pCREB/c‐Fos in *c‐fos* transgenic OS cells depends on MAPK signaling.

To further demonstrate that EGFR signaling is mainly affecting the expression of endogenous but not transgenic *c‐fos*, primary OS cells isolated from *p53* ^f/f^ *Rb*1^f/f^ *Osx*‐Cre mice were employed. It has been reported, that *c‐fos* is upregulated in primary OS cells isolated from these mice (Walkley *et al*, [2008](#emmm201809408-bib-0047){ref-type="ref"}). In agreement with the results obtained with primary H2*‐c‐fos*LTR OS cells, also *p53* ^f/f^ *Rb*1^f/f^ *Osx*‐Cre OS cells showed reduced pRSK2/pCREB/Fos protein levels (Fig [4](#emmm201809408-fig-0004){ref-type="fig"}G) and significantly downregulated *c‐fos* mRNA expression after erlotinib treatment (Fig [4](#emmm201809408-fig-0004){ref-type="fig"}H). On the other hand, strong activation of pEGFR/pRSK2/pCREB/c‐Fos was induced after EGF stimulation (Fig [4](#emmm201809408-fig-0004){ref-type="fig"}I). These data indicate that the observed mechanism of EGFR‐dependent activation of c‐Fos via pRSK2/pCREB also applies for bone tumors that are not induced by transgenic *c‐fos*.

Osteoblast‐specific overexpression of the EGFR ligand AREG accelerates OS formation {#emmm201809408-sec-0007}
-----------------------------------------------------------------------------------

Next, we wanted to investigate whether constitutive activation of the EGFR pathway can enhance bone tumor formation. We therefore bred H2‐*c‐fos*LTR mice to mice overexpressing the EGFR ligand Amphiregulin (AREG) under the control of the osteoblast‐specific *col1a1* promoter (*ColAREG*) (Vaidya *et al*, [2015](#emmm201809408-bib-0046){ref-type="ref"}). Double transgenic mice (H2‐*c‐fos*LTR/*ColAREG*) showed significantly increased tumor numbers, size and a tendency of elevated serum ALP levels (Fig [5](#emmm201809408-fig-0005){ref-type="fig"}A--D), indicating that autocrine osteoblast‐specific EGFR activation accelerates OS development.

![Osteoblast‐specific overexpression of the EGFR ligand Amphiregulin accelerates tumor formation in H2*‐c‐fos*LTR mice\
AX‐ray analysis of 6‐month‐old H2*‐c‐fos*LTR and H2‐*c‐fos*LTR/*ColAREG* littermates. Scale bars: 1 cm.BBone tumor number per mouse at 5--6 months of age (*n* = 22 wt, 13 *ColAREG*).CQuantification of tumor size in tibiae at 5--6 months of age (*n* = 22 wt, 13 *ColAREG*).DAlkaline phosphatase (ALP) levels in the serum at endpoint (age = 5--6 months; *n* = 29 wt, 19 *ColAREG*).E*c‐fos* mRNA expression levels in OSs of H2*‐c‐fos*LTR (*n* = 11) and H2*‐c‐fos*LTR/*ColAREG* mice (*n* = 14).F, GWestern blot analysis of bone tumor protein lysates from H2*‐c‐fos*LTR and H2*‐c‐fos*LTR/*ColAREG* mice.Data information: Data are shown as mean ± SEM. *P*‐values were calculated by unpaired, two‐tailed *t*‐test.Source data are available online for this figure.](EMMM-10-e9408-g010){#emmm201809408-fig-0005}

Tumors from double transgenic mice displayed significantly increased AREG protein ([Appendix Fig S2A](#emmm201809408-sup-0001){ref-type="supplementary-material"}) and mRNA expression levels ([Appendix Fig S2B](#emmm201809408-sup-0001){ref-type="supplementary-material"}) and elevated EGFR phosphorylation ([Appendix Fig S2C](#emmm201809408-sup-0001){ref-type="supplementary-material"}). Moreover, they showed significantly increased *c‐fos* mRNA expression levels (Fig [5](#emmm201809408-fig-0005){ref-type="fig"}E), whereas the transgenic *c‐fos* mRNA in the tumor was not significantly changed ([Appendix Fig S2D](#emmm201809408-sup-0001){ref-type="supplementary-material"}). Western blot analysis further revealed that bone tumors of H2‐*c‐fos*LTR/*ColAREG* mice displayed elevated activation of the EGFR downstream proteins pRSK2, pCREB and c‐Fos resulting in elevated proliferation with increased cyclin D1 protein expression (Fig [5](#emmm201809408-fig-0005){ref-type="fig"}F) and decreased apoptosis as shown by reduced cleaved caspase‐3 levels (Fig [5](#emmm201809408-fig-0005){ref-type="fig"}G). These data demonstrate that constitutive AREG‐induced EGFR activation accelerates tumorigenesis in H2‐*c‐fos*LTR mice via enhanced tumor cell proliferation and survival resulting from increased pRSK2/pCREB/c‐Fos signaling.

EGFR and c‐Fos co‐expression correlates with poor survival of human OS patients {#emmm201809408-sec-0008}
-------------------------------------------------------------------------------

To investigate whether our findings in the FOS‐driven OS mouse model are of clinical relevance, we stained biopsies from 52 human OS patients with antibodies directed against EGFR and c‐Fos and divided them, according to their expression levels, into two groups (positive or negative; Fig [6](#emmm201809408-fig-0006){ref-type="fig"}A). In line with published studies (Do *et al*, [2009](#emmm201809408-bib-0007){ref-type="ref"}; Lee *et al*, [2012](#emmm201809408-bib-0021){ref-type="ref"}), we did not find any significant correlation between EGFR expression and overall survival of OS patients (Fig [EV4](#emmm201809408-fig-0004ev){ref-type="fig"}A). Also c‐Fos expression in bone tumors did not show any significant impact on the overall patient survival (Fig [EV4](#emmm201809408-fig-0004ev){ref-type="fig"}B).

![EGFR and c‐Fos co‐expression in human OS negatively correlates with patient survival\
ARepresentative images of OS biopsies stained with antibodies against EGFR and c‐Fos. Scale bars: 50 μm.BKaplan--Meier survival curve comparing the survival of patients with EGFR and c‐Fos double‐positive OSs against patients without co‐expression of both proteins (*n* = 52).CGene expression correlation analysis of several cancer‐associated RTKs with *FOS* in human OS (data analyzed from publicly available dataset E‐GEOD‐39058).Data information: *P*‐values were calculated by log‐rank (Mantel--Cox) test comparing the two Kaplan--Meier curves (B) or by unpaired, two‐tailed *t*‐test (C).](EMMM-10-e9408-g012){#emmm201809408-fig-0006}

![EGFR or c‐Fos expression does not significantly correlate with patient survival\
AKaplan--Meier survival curve correlating EGFR protein levels in the bone tumors with patient survival. *n* = 52.BKaplan--Meier survival curve correlating c‐Fos protein levels in the bone tumors with patient survival. *n* = 52.CGene expression correlation analysis of EGFR ligands with *FOS* in human OS (data analyzed from publicly available dataset E‐GEOD‐39058).Data information: *P*‐values were calculated by log‐rank (Mantel--Cox) test comparing the two Kaplan--Meier curves (A and B) or unpaired, two‐tailed *t*‐test (C).](EMMM-10-e9408-g009){#emmm201809408-fig-0004ev}

However, when we stratified patients according to the co‐expression of EGFR and c‐Fos we found significantly reduced survival of patients with tumors that showed high levels of both proteins (Fig [6](#emmm201809408-fig-0006){ref-type="fig"}B), suggesting that EGFR inhibition might be a possible treatment option for patients suffering from EGFR and FOS double‐positive OS.

Analysis of RNAseq data of human OS from a publicly available dataset \[GSE39058 (Kelly *et al*, [2013](#emmm201809408-bib-0017){ref-type="ref"})\] further revealed that *EGFR* expression significantly correlated with *FOS* expression (Fig [6](#emmm201809408-fig-0006){ref-type="fig"}C). In contrast, except for *PDGFRB*, other cancer‐associated receptor tyrosine kinases (RTKs) showed either negative or no correlation with *FOS* expression (Fig [6](#emmm201809408-fig-0006){ref-type="fig"}C). However, applying linear models for microarray and RNAseq data (LIMMA) analysis revealed that human OS high for both *EGFR* and *FOS* did not show any significantly changed transcriptional profile as compared to double‐negative OS ([Dataset EV1](#emmm201809408-sup-0003){ref-type="supplementary-material"}). Among EGFR ligands, only *TGFa* showed a significant correlation with *FOS* expression, indicating that *TGFa* might be crucial for EGFR activation in FOS‐dependent OSs (Fig [EV4](#emmm201809408-fig-0004ev){ref-type="fig"}C).

EGFR signaling in human OS cell lines and orthotopic tumors {#emmm201809408-sec-0009}
-----------------------------------------------------------

We next tested our hypothesis that EGFR inhibition is more effective in OSs positive for both EGFR and c‐Fos, and analyzed their expression levels in a panel of human OS cell lines. Among six tested cell lines, only the highly aggressive 143b cells showed co‐expression of both EGFR and c‐Fos protein and mRNA, whereas LM7 cells expressed only detectable levels of EGFR but not of c‐Fos (Figs [7](#emmm201809408-fig-0007){ref-type="fig"}A and [EV5](#emmm201809408-fig-0005ev){ref-type="fig"}A). Moreover, EGF stimulation of starved LM7 cells did not induce c‐Fos protein expression, excluding the possibility that c‐Fos gets activated via EGFR signaling in this cell line (Fig [EV5](#emmm201809408-fig-0005ev){ref-type="fig"}B).

![EGFR inhibition decreases tumor progression of human OS cells 143b after orthotopic injection\
AWestern blot analysis showing EGFR and c‐Fos protein levels in human OS cell lines cultured under standard conditions.BCell viability of 143b or LM7 cells cultured for 24 h in medium (+10% FCS) with DMSO (1:2,000) or erlotinib (10 μM; *n* = 3, representative result from three independent experiments, shown as fold change, normalized to DMSO).CCell viability of 143b or LM7 cells cultured for 24 h in medium (+0.5% FCS) containing 1× PBS (contr., 1:200) or EGF (50 ng/ml; *n* = 3, representative result from three independent experiments, shown as fold change, normalized to control).DTreatment scheme: 143b OS cells (10^6^ in 25 μl PBS) were intratibially injected; mice were treated for 14 days with vehicle or erlotinib (50 mg/kg) 7 days after injection, when the tumors started to grow.E143b xenograft growth curve during therapeutic regime (*n* = 8 vehicle, 6 erlotinib; two independent experiments).F143b tumor weight at endpoint (*n* = 8 vehicle, 6 erlotinib; two independent experiments).GTreatment scheme: LM7 OS cells (10^6^ in 25 μl PBS) were intratibially injected; mice were treated for 21 days with vehicle or erlotinib (50 mg/kg) 42 days after injection, when the tumors started to grow.HLM7 xenograft growth curve during therapeutic regime (*n* = 7 vehicle, 5 erlotinib; two independent experiments).ILM7 tumor weight at endpoint (*n* = 7 vehicle, 5 erlotinib, two independent experiments).JIHC analysis of PCNA and cleaved caspase‐3 in 143b‐derived tumors (*n* = 4). Scale bars: 50 μm.KIHC analysis of pCREB and c‐Fos in 143b‐derived tumors (*n* = 5 for pCREB and *n* = 4 for c‐Fos analysis). Scale bars: 50 μm.LWestern blot analysis of pCREB/CREB and p‐c‐Fos/c‐Fos protein expression in lysates directly isolated from 143b xenografts at endpoint, after 14 days of vehicle or erlotinib treatment.Data information: Data are shown as mean ± SEM. *P*‐values were calculated by unpaired, two‐tailed *t*‐test (B, C, F, I, J, and K) or by two‐way ANOVA followed by Bonferroni multiple comparison test (E and H).Source data are available online for this figure.](EMMM-10-e9408-g013){#emmm201809408-fig-0007}

![c‐Fos is essential for 143b cell growth, cell viability, and proliferation\
ARelative *Egfr* and *c‐fos* mRNA expression levels of different human OS cell lines, cultured under standard conditions.BWestern blot analysis of starved LM7 cells, pre‐treated with DMSO (1:1,000) or afatinib (5 μM) for 30 min and stimulated with EGF (50 ng/ml) as indicated.C, D*c‐fos* mRNA (C) and c‐Fos protein expression analysis (D) of 143b cells harboring doxycycline‐inducible c‐fos (sh_FOS) or control (sh_Ctrl) shRNA knock‐down, cultured with (+) or without (−) doxycycline (0.5 μg/ml).E, FCumulative cell growth (E) and MTT assay (F) of 143b sh_Crtl or 143b sh_FOS cells, cultured with (+) or without (−) doxycycline (0.5 μg/ml) (*n* = 3).GQuantification of cleaved caspase‐3‐positive 143b sh_Ctrl or 143b sh_FOS cells, cultured for 48 h with (+) or without (−) doxycycline (0.5 μg/ml) (*n* = 4/5).HQuantification of Ki‐67‐positive 143b sh_Ctrl or 143b sh_FOS cells, cultured for 48 h with (+) or without (−) doxycycline (0.5 μg/ml) (*n* = 6).I, JIHC staining showing EGFR (I) and c‐Fos (J) protein expression in xenografts derived from either 143b or LM7 tumor cells after intratibial injection. Scale bars: 50 μm.KpEGFR IHC staining of 143b and LM7 orthotopic xenograft after vehicle or erlotinib treatment. Scale bars: 50 μm.LIHC analysis of Ki67 in 143b‐derived tumors (*n* = 4). Scale bars: 50 μm.MWestern blot analysis showing cyclin D1 protein levels in 143b tumor lysates after vehicle or erlotinib treatment.Data information: Data are shown as mean ± SEM. *P*‐values were calculated by unpaired, two‐tailed *t*‐test.Source data are available online for this figure.](EMMM-10-e9408-g011){#emmm201809408-fig-0005ev}

In line with our hypothesis, *in vitro* erlotinib treatment significantly reduced the cell viability in 143b cells, but not in LM7 cells (Fig [7](#emmm201809408-fig-0007){ref-type="fig"}B). Conversely, EGF stimulation led to elevated cell viability only in 143b, but not in LM7 cells (Fig [7](#emmm201809408-fig-0007){ref-type="fig"}C), indicating that OS cells become addicted to EGFR signaling only if they express both EGFR and c‐Fos. To demonstrate that c‐Fos is essential in 143b OS cells, we knocked down *c‐fos* in these cells by employing doxycycline‐inducible shRNA (Fig [EV5](#emmm201809408-fig-0005ev){ref-type="fig"}C and D) to show that both cell proliferation and cell viability were reduced in 143b OS cells lacking *c‐fos* (Fig [EV5](#emmm201809408-fig-0005ev){ref-type="fig"}E--H).

An orthotopic OS model mimicking the human disease was employed to investigate whether our findings also hold true *in vivo*. For this purpose, the human OS cell lines 143b and LM7 were injected into the proximal marrow space of the tibia bone of immunosuppressed mice. After tumors had developed, mice were divided into groups with equal mean tumor volumes and treated with erlotinib (50 mg/kg/day) or vehicle (0.5% Methylcellulose; Fig [7](#emmm201809408-fig-0007){ref-type="fig"}D and G). Similar to what was observed *in vitro*, 143b‐derived xenografts showed high EGFR and c‐Fos protein expression, whereas LM7‐induced tumors only expressed EGFR (Fig [EV5](#emmm201809408-fig-0005ev){ref-type="fig"}I) but no c‐Fos (Fig [EV5](#emmm201809408-fig-0005ev){ref-type="fig"}J). Importantly and in agreement with patient survival data (Fig [6](#emmm201809408-fig-0006){ref-type="fig"}B), xenografts from EGFR and c‐Fos double‐positive 143b cells were more aggressive, resulting in significantly shorter median survival and twofold to threefold increased tumor progression as compared to LM7‐derived tumors (Yuan *et al*, [2009](#emmm201809408-bib-0057){ref-type="ref"}; Ren *et al*, [2015b](#emmm201809408-bib-0038){ref-type="ref"}). Erlotinib treatment strongly reduced EGFR phosphorylation in both xenograft models (Fig [EV5](#emmm201809408-fig-0005ev){ref-type="fig"}K). Erlotinib‐induced tumor reduction at the endpoint was exclusively detectable in 143b‐derived OS, whereas LM7‐derived OS did not show any significant differences in tumor size or weight after erlotinib therapy (Fig [7](#emmm201809408-fig-0007){ref-type="fig"}D--I). The results from this preclinical trial demonstrate that EGFR inhibition only reduces OS progression in tumors that co‐express both EGFR and c‐Fos (Fig [7](#emmm201809408-fig-0007){ref-type="fig"}E and F) confirming EGFR as a driver in this subclass of OS.

We next assessed whether in the 143b OS xenograft model EGFR inhibition also affected proliferation and survival via pCREB/c‐Fos as seen in H2‐*c‐fos*LTR mice. IHC stainings revealed significantly reduced levels of PCNA and increased numbers of cleaved caspase‐3‐positive cells in tumors after erlotinib treatment (Fig [7](#emmm201809408-fig-0007){ref-type="fig"}J). This, together with reduced protein levels of Ki‐67 and cyclin D1 (Fig [EV5](#emmm201809408-fig-0005ev){ref-type="fig"}L and M), indicates that EGFR plays an essential role during proliferation and apoptosis in orthotopically injected 143b OS cells. Additionally, we found significantly reduced pCREB/c‐Fos levels in 143b‐derived tumors after erlotinib treatment as shown by IHC (Fig [7](#emmm201809408-fig-0007){ref-type="fig"}K) and Western blot analysis (Fig [7](#emmm201809408-fig-0007){ref-type="fig"}L). In summary, these data provide strong evidence that EGFR‐dependent activation of pCREB/c‐Fos represents a driving pathway in EGFR/Fos double‐positive OS.

Discussion {#emmm201809408-sec-0010}
==========

EGFR inhibition in human OS cell lines has been shown to effectively decrease cell migration, cell invasion and colony formation (Messerschmitt *et al*, [2008](#emmm201809408-bib-0027){ref-type="ref"}). Other studies suggested that EGFR inhibition has no significant influence on cell proliferation, but enhances the anti‐tumor effects of starvation or chemotherapy‐induced cell stress *in vitro* (Sevelda *et al*, [2015](#emmm201809408-bib-0041){ref-type="ref"}). Our study shows that EGFR is a driver of OS, at least in a subgroup of patients suffering from EGFR and c‐Fos double‐positive tumors.

We found significantly reduced OS formation in H2*‐c‐fos*LTR mice, when we either genetically deleted EGFR or pharmacologically inhibited the receptor. Moreover, cell‐type‐specific EGFR knock‐out models revealed that EGFR signaling in osteoblasts is the driving force essential for c‐Fos‐dependent OS formation, whereas myeloid‐cell‐specific deletion of EGFR did not affect osteosarcomagenesis. This is in contrast to our previous findings in colorectal and hepatocellular carcinoma, where EGFR expression in myeloid cells was found to be essential for tumor formation (Lanaya *et al*, [2014](#emmm201809408-bib-0020){ref-type="ref"}; Srivatsa *et al*, [2017](#emmm201809408-bib-0043){ref-type="ref"}), indicating that the tumorigenic role of EGFR varies depending on the tumor and cell type.

As bone tumors in H2‐*c‐fos*LTR mice arise from the osteoblastic lineage (Grigoriadis *et al*, [1993](#emmm201809408-bib-0009){ref-type="ref"}), we hypothesize that the tumor cell‐intrinsic function of EGFR might be similar to its role in pancreatic ductal adenocarcinoma (PDAC), where EGFR deletion or inhibition was shown to ameliorate KRAS‐driven PDAC (Ardito *et al*, [2012](#emmm201809408-bib-0003){ref-type="ref"}; Navas *et al*, [2012](#emmm201809408-bib-0032){ref-type="ref"}). It would be of interest to address whether the molecular mechanisms in c‐Fos‐dependent OSs also hold true for KRAS‐mutated PDACs in which c‐Fos was also reported to be a major driver (Guo *et al*, [2015](#emmm201809408-bib-0010){ref-type="ref"}; You *et al*, [2016](#emmm201809408-bib-0056){ref-type="ref"}).

Clinical studies have linked expression of the EGFR ligand AREG to poor prognosis of patients suffering from carcinomas such as pancreatic, breast, or colorectal cancer (Willmarth & Ethier, [2008](#emmm201809408-bib-0053){ref-type="ref"}; Yamada *et al*, [2008](#emmm201809408-bib-0055){ref-type="ref"}; Wang *et al*, [2016](#emmm201809408-bib-0050){ref-type="ref"}). A recent study by Liu *et al* ([2015](#emmm201809408-bib-0023){ref-type="ref"}) concluded that AREG also promotes cell migration and metastatic capacity of human OS cells as shRNA‐mediated knock‐down of AREG resulted in significantly less lung metastasis nodules after i.v. injection. In line with this study, we found significantly elevated tumor formation and progression when we boosted EGFR signaling in bone tumors by crossing H2‐*c‐fos*LTR mice to mice that overexpress AREG under an osteoblast‐specific promoter (*ColAREG*), suggesting that AREG could indeed be a clinically relevant molecule in OS development.

Mechanistically, we found that EGFR is essential for proliferation, survival, and MAPK‐dependent activation of pCREB/c‐Fos in bone tumors of H2*‐c‐fos*LTR mice and in orthotopically injected human 143b OS cells, which are positive for both EGFR and Fos. As it has been reported that the MAPK‐signaling protein RSK2 is essential for progression of OSs in H2*‐c‐fos*LTR mice (David *et al*, [2005](#emmm201809408-bib-0006){ref-type="ref"}), it is likely that EGFR acts as the upstream receptor controlling RSK2 phosphorylation, which in turn activates and stabilizes the c‐Fos protein leading to OS progression. In addition, it has been shown that endogenous *c‐fos* expression levels directly correlate with tumor formation in H2‐*c‐fos*LTR mice (Wang *et al*, [1995](#emmm201809408-bib-0048){ref-type="ref"}). Mice heterozygous for *c‐fos* (*c‐fos* ^+/−^) developed about 50% less OSs, whereas *c‐fos* full knock‐out mice (*c‐fos* ^−/−^) were nearly tumor‐free (Wang *et al*, [1995](#emmm201809408-bib-0048){ref-type="ref"}). In this study, we discovered that EGFR signaling is essential for endogenous *c‐fos* mRNA expression. Interestingly, RSK2 deletion was shown not to affect endogenous *c‐fos* transcription in bone tumors of H2*‐c‐fos*LTR mice (David *et al*, [2005](#emmm201809408-bib-0006){ref-type="ref"}). Therefore, we speculate that EGFR controls *c‐fos* transcription directly via ERK1/2, which has indeed been shown to induce *c‐fos* mRNA expression after binding to RSK2‐independent phosphorylation sites on the carboxyl‐terminal transactivation domain (Monje *et al*, [2003](#emmm201809408-bib-0029){ref-type="ref"}). While we can distinguish transgenic *c‐fos* mRNA from total *c‐fos* mRNA, we cannot distinguish the c‐Fos protein expressed from the transgene. Therefore, we can formally not rule out the possibility that EGFR also affects transgenic c‐Fos protein levels. To confirm that EGFR mainly plays a role in endogenous c‐Fos activation, we used an independent preclinical OS model, which is based on osteoblast‐specific deletion of the two tumor suppressor genes p53 and Rb1 (Walkley *et al*, [2008](#emmm201809408-bib-0047){ref-type="ref"}). Also in this model, *c‐fos* is upregulated in *p53* ^f/f^ *Rb1* ^f/f^ *Osx*‐Cre OS cells suggesting a potential tumorigenic role for c‐Fos in this model (Walkley *et al*, [2008](#emmm201809408-bib-0047){ref-type="ref"}). We found that *c‐fos* mRNA and pRSK2/pCREB/c‐Fos protein levels were significantly reduced after EGFR inhibition, demonstrating that the here proposed mechanism does likely not depend on the *c‐fos* transgene.

By analyzing biopsies from human OS patients, we could not detect any significant impact of EGFR expression on overall patient survival, which is similar to previous reports (Do *et al*, [2009](#emmm201809408-bib-0007){ref-type="ref"}; Lee *et al*, [2012](#emmm201809408-bib-0021){ref-type="ref"}). However, histological analysis of OS patients by Wen *et al* ([2007](#emmm201809408-bib-0052){ref-type="ref"}) revealed high EGFR expression in 4 out of 5 (80%) recurring lesions, whereas only 14 out of 37 (38%) primary tumors showed such high EGFR protein levels. Surprisingly, one study reported a positive correlation between EGFR expression and good clinical outcome in high‐grade OS patients, which might be due to the fact that patients with high EGFR levels show better responses to conventional therapies (Kersting *et al*, [2007](#emmm201809408-bib-0018){ref-type="ref"}). In contrast, another recent report found a significant correlation between high EGFR levels in OS and reduced patient survival (Wang *et al*, [2018](#emmm201809408-bib-0051){ref-type="ref"}). Since OS is a rare tumor, the few numbers of OS patients preclude a comprehensive investigation. Thus, the potential of anti‐EGFR agents in the treatment of human OS remained elusive, raising the need to identify prognostic molecular markers for future treatment approaches. When we categorized OS patients according to the co‐expression of both proteins, EGFR and c‐Fos, we found significantly reduced overall survival within this sub‐population. Thus, staining OS patient biopsies for these two biomarkers could be a valuable approach to predict disease progression. Although c‐Fos could be downstream of many other RTKs expressed in OS, RNAseq analysis revealed that besides *EGFR,* only *PDGFRB* significantly correlated with *FOS* expression indicating that PDGFRβ signaling might also act as an upstream activator for c‐Fos‐dependent OS. Previous reports have shown that PDGFR is indeed frequently overexpressed in OS and preclinical studies further suggested a tumor‐promoting role for PDGFR (McGary *et al*, [2002](#emmm201809408-bib-0026){ref-type="ref"}; Kubo *et al*, [2008](#emmm201809408-bib-0019){ref-type="ref"}).

In future, EGFR and c‐Fos could be useful biomarkers to stratify OS patients. A previous report showed that *c‐fos* expression changed in human squamous cell carcinomas after EGFR‐TKI treatment and correlated with therapy response in xenograft models (Jimeno *et al*, [2006](#emmm201809408-bib-0015){ref-type="ref"}). However, the potential use of FOS for predicting therapy response was not demonstrated. In the current study, we show that only OSs which express c‐Fos respond to anti‐EGFR treatment, thereby identifying FOS as a potent predictive biomarker in OS patients. We found that orthotopic bone tumors induced with the EGFR and c‐Fos expressing 143b OS cell line were responsive to anti‐EGFR treatment, whereas LM7 cells, which only express EGFR but not c‐Fos, did not respond to erlotinib. A recent study also reported that treatment with cetuximab, a clinically used anti‐EGFR antibody, led to significantly reduced tumor formation after intratibial injection of 143b cells (Gvozdenovic *et al*, [2017](#emmm201809408-bib-0012){ref-type="ref"}). Taken together, our results indicate that anti‐EGFR therapies will be successful in patients with FOS‐positive OS, where EGFR seems to be a tumor driver. These results might allow better OS patient stratification and therefore offer new therapeutic approaches for a rare tumor type for which there are basically no treatment options.

Materials and Methods {#emmm201809408-sec-0011}
=====================

Mice {#emmm201809408-sec-0012}
----

*Egfr* ^f/f^ (Natarajan *et al*, [2007](#emmm201809408-bib-0031){ref-type="ref"}), *Egfr* ^wa2/wa2^ (Luetteke *et al*, [1994](#emmm201809408-bib-0024){ref-type="ref"})*, Runx2‐Cre* (Rauch *et al*, [2010](#emmm201809408-bib-0036){ref-type="ref"}), *LysM‐Cre* (Clausen *et al*, [1999](#emmm201809408-bib-0005){ref-type="ref"}), H2‐*c‐fos*LTR (Ruther *et al*, [1989](#emmm201809408-bib-0040){ref-type="ref"}), and *ColAREG* (Vaidya *et al*, [2015](#emmm201809408-bib-0046){ref-type="ref"}) mice have been described previously. *Egfr* ^f/f^, H2‐*c‐fos*LTR, *Runx2‐Cre,* and *LysM‐Cre* mice were maintained on a pure C57/BL6J background. *Egfr* ^wa2/wa2^ and *ColAREG* mice were maintained on a mixed genetic background. Both males and females were used indiscriminately. Mice were analyzed between 2 and 7 months of age as indicated in the corresponding figure legend. The animals were monitored and analyzed without randomization or blinding. Mice were kept in the animal facility of the Medical University of Vienna with unlimited access to both water and standard laboratory chow under a light--dark cycle of 12 h at 22°C in accordance with institutional policies and federal guidelines. All animal experiments conducted were compliant with federal laws and guidelines of the Medical University of Vienna.

Cell culture {#emmm201809408-sec-0013}
------------

Human OS cell lines U2OS, SaOS2, HOS, 143b, and MG63 were purchased from ATCC (Manassas, VA). The LM‐7 OS cell line (Jia *et al*, [1999](#emmm201809408-bib-0014){ref-type="ref"}) was provided by Dr. Eugenie S. Kleinerman from the M.D. Anderson Cancer Center (University of Texas). 143b OS cells have been reported not to carry any EGFR mutations (Wen *et al*, [2007](#emmm201809408-bib-0052){ref-type="ref"}). 143b cells were cultured in DMEM supplemented with 10% FCS (Sigma), and LM7 cells were cultured in MEM with non‐essential amino acids, pyruvate, and 10% FCS (Sigma). Primary mouse OS cells were isolated and cultured as previously described (Grigoriadis *et al*, [1993](#emmm201809408-bib-0009){ref-type="ref"}). For EGFR inhibitor experiments, sub‐confluent cells were treated with indicated concentrations of erlotinib (Santa Cruz Biotechnology) for 24 h in normal growth medium (DMEM +10% FCS; Sigma). For *in vitro* stimulation experiments, cells were serum‐starved overnight and pre‐treated for 30 min with DMSO (1:1,000) or inhibitors against EGFR (5 μM afatinib, Santa Cruz Biotechnology), PDK‐1 (10 μM GSK2334470, Selleckchem), mTor (10 nM rapamycin, Sigma), or ERK1/2 (10 μM U0126, Cell Signaling Technology). Afterward, cells were stimulated for 0, 5, or 30 min with 50 ng/ml recombinant EGF (PeproTech). All cell lines were tested and showed no mycoplasma contamination.

Gene silencing using shRNA {#emmm201809408-sec-0014}
--------------------------

To knock down (KD) *FOS*, HEK 293T cells were transduced with lentiviral *FOS* shRNA expression vectors (Tet‐pLKO‐neo‐FOS) with pCMV‐Δ89 plasmid and pVSV‐G envelop plasmid, and then lentiviral particles from culture supernatants were used to infect 143b cells, which were selected with Neomycin (500 μg/ml) for 1 week.

shRNA oligo primer sequences for FOS were as follows: Fw: CCG GTC TGC TTT GCA GAC CGA GAT TCT CGA GAA TCT CGG TCT GCA AAG CAG ATT TTT G and Rv: AAT TCA AAA ATC TGC TTT GCA GAC CGA GAT TCT CGA GAA TCT CGG TCT GCA AAG CAG A.

Immunofluorescence staining {#emmm201809408-sec-0015}
---------------------------

For *in vitro* immunofluorescence (IF) staining, cells were seeded on chamber slides (2‐well or 8‐well) and cultured/treated as indicated in the figure legends. After removing the medium, cells were washed with PBS and fixed with 4% PFA for 20 min at room temperature. The fixed cells were washed and permeabilized with 0.1% Triton X‐100 in PBS for 10 min at room temperature. Afterward, cells were washed and blocked with 2% BSA and 5% normal goat serum in PBS for 1 h at room temperature. Antibodies (see [Appendix Table S1](#emmm201809408-sup-0001){ref-type="supplementary-material"}) were incubated in blocking buffer overnight at 4°C. After washing with PBS, 100 μl of secondary antibody (donkey anti‐rabbit Alexa Fluor 555) diluted 1:500 in blocking buffer was added and incubated for an hour at room temperature. After washing with PBS, the slide was mounted with aqueous mounting medium and observed using a fluorescent microscope.

MTT assay {#emmm201809408-sec-0016}
---------

Cells were seeded at a density of 500 cells/well in 96‐well plates and cultured for 48, 96, and 144 h with/without doxycycline (500 ng/ml), respectively. Subsequently, 25 μl of MTT reagent (5 mg/ml) was added to each well and incubated for 2 h at 37°C. After removing media, wells were washed with PBS and then the remaining crystals were dissolved in dimethyl sulfoxide. The absorbance was evaluated at 570 nm (background is 630 nm). The assays were performed in triplicate.

Cell viability assay {#emmm201809408-sec-0017}
--------------------

For cell viability assay, cells (1.5 × 10^3^/cm^2^ for LM7; 1.5 × 10^2^/cm^2^ for 143b) were seeded in white, opaque‐walled 96‐well plates (Thermo Fisher). After 24 h, cells were treated with DMSO (1:2,000) or erlotinib (10 μM) in normal growth medium containing 10% FCS or stimulated with EGF (50 ng/ml) in growth medium containing 0.5% FCS. After 24 h of treatment/stimulation, cell viability was measured using the CellTiter‐Glo® Luminescent Cell Viability Assay Kit (Promega) according to manufacturer\'s instructions.

*In vivo* imaging {#emmm201809408-sec-0018}
-----------------

For X‐ray analysis, mice were anesthetized and imaging was performed using a Mobilett XP mobile X‐ray machine (Siemens). Tumor number was quantified from X‐ray images using Photoshop CS6 (Adobe), and tumor size was measured with ImageJ 1.49v (Wayne Rasband, NIH, USA).

Imaging experiments were conducted with a small animal computed tomography (CT) and positron emission tomography (PET) scanner (Siemens Inveon™ multimodal μSPECT/PET/CT; Siemens Preclinical Solutions, Knoxville, USA). Mice were anesthetized with 1.5--2% isoflurane mixed with oxygen (1.5 l/min) to avoid movement during the imaging procedure. Subsequently, for the PET image acquisition mice were administered fluorine‐18 sodium fluoride (Na\[^18^F\]F) (21.09 ± 3.86 MBq; 70 ± 19 μl) via retro‐orbital injection. After an accumulation time of 60 min, a 10‐min static PET acquisition and a subsequent high‐resolution whole‐body CT scan were performed. Vital parameters, such as respiration and body temperature, were recorded continuously using a dedicated physiological monitoring system (bioVet; m2mimaging, Cleveland, OH, USA).

CT raw data were reconstructed with a Feldkamp algorithm using a Ramp filter followed by default beam‐hardening correction. PET data reconstruction was performed with an OSEM 3D/OP‐MAP algorithm with default parameters and attenuation corrected on the basis of CT measurements. All data were normalized and corrected for random, dead time, radioactive decay, and weight of the animal. A calibration factor was applied to the data in order to convert the units of the small animal PET images into absolute radioactivity concentrations, expressed as standardized uptake values (SUV; g/ml). PET and CT images were co‐registered through an automatically generated spatial transformation matrix. Biomedical image analysis was accomplished using the Inveon Research Workplace Software (IRW; Siemens Medical Solutions, Knoxville, TN, USA). For image quantification, cylindrical volumes of interest were drawn. The respective Na\[^18^F\]F uptake in the delineated areas was expressed as SUV normalized to body weight.

PET experiments to study tissue distribution of \[^11^C\]erlotinib were conducted at the Austrian Institute of Technology on a microPET Focus 220 system (Siemens Medical Solutions) as described in detail elsewhere (Traxl *et al*, [2017](#emmm201809408-bib-0045){ref-type="ref"}). In brief, 6‐month‐old female H2‐*c‐fos*LTR/*Egfr* ^wt^ mice (*n *=* *3) underwent under isoflurane anesthesia 90‐min dynamic PET scans after i.v. injection of a mixture of \[^11^C\]erlotinib (47 ± 12 MBq) and unlabeled erlotinib hydrochloride (Apollo Scientific, Bredbury, UK) at a dose of 2mg/kg. At the end of the \[^11^C\]erlotinib PET scan, animals received an i.v. injection of Na\[^18^F\]F (injected amount: 5 ± 1 MBq) followed by a 20‐min static PET scan. PET data were reconstructed as described (Traxl *et al*, [2017](#emmm201809408-bib-0045){ref-type="ref"}). Tumor volumes of interest were outlined on the dynamic \[^11^C\]erlotinib PET images guided by the static Na\[^18^F\]F PET images. Radioactivity concentration in tumors was expressed in SUV units and multiplied by the administered erlotinib dose of 2 mg/kg to obtain mass concentrations of erlotinib (μg/g).

Intratibial tumor cell injection and *in vivo* erlotinib treatment {#emmm201809408-sec-0019}
------------------------------------------------------------------

For intratibial injection of tumor cells, 8‐ to 12‐week‐old female nude mice were anesthetized and 143b or LM7 tumor cells (10^6^ in 25 μl 1× PBS) were injected through the knee to the bone marrow cavity of the left proximal tibia. Seven days (143b) or 6 weeks (LM7) after injection, mice were randomized and treated for 14 days (143b) or 21 days (LM7) with erlotinib (50 mg/kg bw, i.p.) or the vehicle (0.5% Methylcellulose). Tumor volume was calculated by caliper measurements of the injected tibia bone using the formula Vol. = length × width^2^/2 minus the volume of the healthy, non‐injected leg as described elsewhere (Gvozdenovic *et al*, [2016](#emmm201809408-bib-0011){ref-type="ref"}). For long‐term treatment, 2‐month‐old male H2*‐c‐fos*LTR mice were divided into two groups and treated with either erlotinib (25 mg/kg bw, 5×/week, i.p.) or the vehicle (0.5% Methylcellulose, 5×/week, i.p.; Politi *et al*, [2006](#emmm201809408-bib-0035){ref-type="ref"}). After 4 weeks of treatment, mice were left untreated for 4 weeks until the treatment regime started again. Tumor number and size as well as serum ALP levels were quantified monthly.

Human mRNA expression data {#emmm201809408-sec-0020}
--------------------------

For human mRNA expression data, the publicly available RNAseq datasets E‐GEOD‐39058 (Kelly *et al*, [2013](#emmm201809408-bib-0017){ref-type="ref"}) were downloaded from Gene Expression Omnibus and analyzed with the GEOquery package of R. The GSE39058 dataset also included recurrence‐free survival information. Expression data were stratified into EGFR/FOS low and high expressers using the surv_cutpoint function of survminer using recurrence‐free survival as target variable. The gene expression profile EGFR/FOS double low vs. double high was analyzed using the LIMMA package of R.

Human OS tissue microarray {#emmm201809408-sec-0021}
--------------------------

The human OS TMA was purchased from Novus Biologicals (Catalog Number: NBP2‐30289). The TMA contained 4‐μm‐thick sections of 59 bone cancer biopsies and one control biopsy from a non‐cancer patient. Seven patients had to be excluded from the analysis due to: unknown cause of death (*n* = 2), died of heart disease (*n* = 2), survival information not available (*n* = 2), and tissue lost during IHC staining procedure (*n* = 1). The remaining 52 biopsies, which were analyzed in the study, were derived from 39 male and 13 female patients with an average age of 20.2 ± 11.2 years.

Immunohistochemistry {#emmm201809408-sec-0022}
--------------------

For immunohistological stainings, samples were fixed in 4% PBS‐buffered formalin, decalcified in 0.5 M EDTA (pH 8.0) and embedded in paraffin. Immunohistochemistry was performed on 3‐μm‐thick sections. Primary antibodies (for a full list, see [Appendix Table S1](#emmm201809408-sup-0001){ref-type="supplementary-material"}) were incubated overnight at 4°C followed by HRP‐based immunoreactivity detection (Cell Signaling Technology). Non‐specific binding was blocked with TBS‐T containing 2% BSA and 5% normal goat serum. Quantification of IHC stainings was performed using the ImageJ plugin ImmunoRatio (version: 1.0c, Jorma Isola and Vilppu Tuominen, University of Tampere). For analysis of EGFR/c‐Fos expression in human OS, two consecutive sections from a commercially available TMA (Novus, NBP2‐30289) were stained with antibodies directed against EGFR (Cell Signaling Technology, \#4267) and c‐Fos (Santa Cruz Biotechnology, SC‐52). For quantification, cores were graded according to positive cells by two independent investigators whereby more than 60% positive cells were considered as positive/high. The results were afterward double‐checked using an automatized histology quantification program (Definiens Tissue Studio^®^ 4.0).

RNA isolation, real‐time qRT--PCR analysis {#emmm201809408-sec-0023}
------------------------------------------

RNA isolation and qRT--PCR analysis were performed as described previously (Linder *et al*, [2018](#emmm201809408-bib-0022){ref-type="ref"}). For a full list of primers used, see [Appendix Table S2](#emmm201809408-sup-0001){ref-type="supplementary-material"}.

Western blot analysis {#emmm201809408-sec-0024}
---------------------

Western blot analysis was performed as previously described (Sibilia *et al*, [2000](#emmm201809408-bib-0042){ref-type="ref"}). For a full list of the antibodies used, please see [Appendix Table S1](#emmm201809408-sup-0001){ref-type="supplementary-material"}.

ELISA {#emmm201809408-sec-0025}
-----

Mouse Amphiregulin ELISA (Thermo Fisher) was performed according to manufacturer\'s instructions. Protein concentration was analyzed using Bradford protein assay (Bio‐Rad).

Analysis of alkaline phosphatase {#emmm201809408-sec-0026}
--------------------------------

Alkaline phosphatase serum levels were measured using diagnostic ALP test stripes (Reflotron, Roche) and read on an automatic Reflotron analyzer (Roche).

Statistical methods {#emmm201809408-sec-0027}
-------------------

Sample size of *in vivo* experiments was chosen based on previous experience with similar studies in the laboratory. For analyses of IHC and qRT--PCR data, univariable comparisons of expression values between groups were analyzed by unpaired two‐tailed Student\'s *t*‐test with *f*‐test to ensure comparable variances between the groups. If the variances were significantly different, as measured by *f*‐test, unpaired two‐tailed Student\'s *t*‐test with Welch\'s correction was performed. For analysis of more than two groups/time‐points (e.g., erlotinib long‐term treatment experiment), two‐way ANOVA with Bonferroni post‐test was applied. For comparison of survival curves, log‐rank (Mantel--Cox) tests were performed. Data are shown as mean ± SEM. A *P*‐value below 0.05 was considered statistically significant. For analyses and calculation, GraphPad Prism 6 software was used.
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 {#emmm201809408-sec-0031}

###### The paper explained

Problem {#emmm201809408-sec-0032}
-------

Osteosarcoma (OS) is a rare tumor affecting the bone and occurs mainly in children and young adults. Besides surgery and chemotherapy, there are no other therapeutic options and there has been no survival improvement for OS patients in the last 40 years. The epidermal growth factor receptor (EGFR) is highly expressed in OS patients. However, because of the low incidence of OSs, clinical studies with EGFR inhibitors could so far not demonstrate a clear therapeutic benefit.

Results {#emmm201809408-sec-0033}
-------

Here, we report that EGFR promotes OS development via a signaling pathway involving RSK2/CREB leading to upregulation of the AP‐1 transcription factor c‐Fos. Genetic deletion or pharmacological inhibition of EGFR resulted in reduced OS formation and progression in mouse models of OS by inhibiting the proliferation and survival of cancer‐initiating osteoblastic cells. Furthermore, we found that patients suffering from OSs, which are positive for both EGFR and c‐Fos, show significantly reduced overall survival. Preclinical studies using orthotopic human OS Xenografts revealed that only human OSs co‐expressing EGFR and FOS responded to anti‐EGFR therapy, whereas tumors that were EGFR‐positive but EGFR‐negative for FOS did not respond.

Impact {#emmm201809408-sec-0034}
------

Our results demonstrate that c‐Fos and EGFR represent novel biomarkers predicting response to anti‐EGFR treatment in OS patients. Thus, our findings will allow better patient stratification in the future and our study recommends targeted anti‐EGFR therapies for OS patients positive for Fos and EGFR.
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